Home Data Calendar Blog

BLI

Tables

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NA 0.00 NA NA NA

Weighted Average Number Of Diluted Shares Outstanding NA 68.38 67.99 67.70 NA 67.21 66.79 65.26 NA 53.60 3.11 NA NA NA NA NA

Weighted Average Number Of Shares Outstanding Basic NA 68.38 67.99 67.70 NA 67.21 66.79 65.26 NA 53.60 3.11 NA NA NA NA NA

Earnings Per Share Basic -0.41 -0.32 -0.38 -0.32 -0.27 -0.30 -0.27 -0.24 0.17 -0.16 -4.25 NA NA NA NA NA

Earnings Per Share Diluted -0.41 -0.32 -0.38 -0.32 -0.27 -0.30 -0.27 -0.24 0.17 -0.16 -4.25 NA NA NA NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Common Stock Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	0.00	NA	NA	NA
Weighted Average Number Of Diluted Shares Outstanding	NA	68.38	67.99	67.70	NA	67.21	66.79	65.26	NA	53.60	3.11	NA	NA	NA	NA	NA
Weighted Average Number Of Shares Outstanding Basic	NA	68.38	67.99	67.70	NA	67.21	66.79	65.26	NA	53.60	3.11	NA	NA	NA	NA	NA
Earnings Per Share Basic	-0.41	-0.32	-0.38	-0.32	-0.27	-0.30	-0.27	-0.24	0.17	-0.16	-4.25	NA	NA	NA	NA	NA
Earnings Per Share Diluted	-0.41	-0.32	-0.38	-0.32	-0.27	-0.30	-0.27	-0.24	0.17	-0.16	-4.25	NA	NA	NA	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Revenue From Contract With Customer Excluding Assessed Tax 17.84 21.40 19.15 20.21 23.19 24.32 19.25 18.63 21.75 18.21 10.57 13.78 16.62 15.67 11.76 12.64

Revenues 17.84 21.40 19.15 20.21 23.19 24.32 19.25 18.63 21.75 18.21 10.57 13.78 16.62 15.67 11.76 12.64

Cost Of Goods And Services Sold 5.84 6.37 6.22 6.38 7.23 8.91 6.52 6.18 6.94 5.40 3.61 3.80 4.23 4.00 2.19 NA

Gross Profit 12.00 15.03 12.93 13.83 15.96 15.41 12.73 12.45 14.81 12.81 6.96 9.98 12.39 11.67 9.57 9.85

Operating Expenses 41.70 36.56 38.47 35.10 33.77 35.39 30.58 27.60 26.64 20.99 19.11 18.21 15.67 15.95 15.17 NA

Research And Development Expense 8.48 8.98 18.18 17.57 15.80 16.20 13.54 13.03 14.00 10.42 11.84 10.98 9.84 10.19 9.64 NA

General And Administrative Expense NA NA 13.02 11.72 10.45 12.26 11.72 8.97 7.78 7.23 4.19 4.00 3.50 3.14 3.08 NA

Selling General And Administrative Expense 30.77 26.52 NA NA 17.97 19.20 NA NA NA NA NA NA NA NA NA NA

Selling And Marketing Expense NA NA 7.27 5.81 7.52 6.94 5.32 5.61 4.86 3.34 3.08 3.23 2.33 2.62 2.45 NA

Operating Income Loss -29.70 -21.54 -25.55 -21.27 -17.81 -19.98 -17.85 -15.15 -11.83 -8.18 -12.15 -8.23 -3.28 -4.28 -5.60 NA

Interest Expense 0.23 0.23 0.23 0.22 0.23 0.23 0.36 0.35 0.36 0.36 0.36 0.36 0.36 0.36 0.35 NA

Interest Expense Debt 0.20 0.20 0.20 0.20 0.30 0.20 0.40 0.40 0.30 0.40 0.40 0.40 0.20 0.40 0.40 NA

Interest Paid Net 0.14 0.14 0.14 0.14 0.14 0.15 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34 NA NA

Allocated Share Based Compensation Expense 5.05 5.18 6.57 5.39 5.14 5.96 5.63 4.49 5.85 2.54 1.35 1.18 1.00 0.99 0.95 NA

Income Tax Expense Benefit 0.05 0.02 0.00 0.02 -0.15 0.05 0.03 0.02 0.03 0.12 0.01 0.02 0.01 0.02 0.01 NA

Income Taxes Paid 0.03 NA NA NA 0.00 0.00 NA NA 0.09 0.01 NA NA 0.00 0.02 NA NA

Other Comprehensive Income Loss Net Of Tax 0.01 0.00 -0.02 NA NA NA NA NA NA NA NA NA NA NA NA NA

Net Income Loss -29.30 -21.57 -25.75 -21.43 -17.73 -20.40 -18.15 -15.44 -12.13 -8.60 -12.43 -8.43 -3.46 -4.45 -6.18 -4.21

Comprehensive Income Net Of Tax -29.29 -21.57 -25.77 -21.43 -17.73 -20.40 -18.15 -15.44 -12.13 -8.60 -12.43 -8.43 -3.46 -4.45 -6.18 NA

Net Income Loss Available To Common Stockholders Basic -29.30 -21.57 -25.75 -21.43 -17.73 -20.40 -18.15 -15.44 -12.13 -8.74 -13.23 -9.22 -4.27 -5.25 -6.98 NA

Net Income Loss Available To Common Stockholders Diluted -29.30 -21.57 -25.75 -21.43 -17.73 -20.40 -18.15 -15.44 -12.13 -8.74 -13.23 -9.22 -4.27 -5.25 -6.98 NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Revenue From Contract With Customer Excluding Assessed Tax	17.84	21.40	19.15	20.21	23.19	24.32	19.25	18.63	21.75	18.21	10.57	13.78	16.62	15.67	11.76	12.64
Revenues	17.84	21.40	19.15	20.21	23.19	24.32	19.25	18.63	21.75	18.21	10.57	13.78	16.62	15.67	11.76	12.64
Cost Of Goods And Services Sold	5.84	6.37	6.22	6.38	7.23	8.91	6.52	6.18	6.94	5.40	3.61	3.80	4.23	4.00	2.19	NA
Gross Profit	12.00	15.03	12.93	13.83	15.96	15.41	12.73	12.45	14.81	12.81	6.96	9.98	12.39	11.67	9.57	9.85
Operating Expenses	41.70	36.56	38.47	35.10	33.77	35.39	30.58	27.60	26.64	20.99	19.11	18.21	15.67	15.95	15.17	NA
Research And Development Expense	8.48	8.98	18.18	17.57	15.80	16.20	13.54	13.03	14.00	10.42	11.84	10.98	9.84	10.19	9.64	NA
General And Administrative Expense	NA	NA	13.02	11.72	10.45	12.26	11.72	8.97	7.78	7.23	4.19	4.00	3.50	3.14	3.08	NA
Selling General And Administrative Expense	30.77	26.52	NA	NA	17.97	19.20	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Selling And Marketing Expense	NA	NA	7.27	5.81	7.52	6.94	5.32	5.61	4.86	3.34	3.08	3.23	2.33	2.62	2.45	NA
Operating Income Loss	-29.70	-21.54	-25.55	-21.27	-17.81	-19.98	-17.85	-15.15	-11.83	-8.18	-12.15	-8.23	-3.28	-4.28	-5.60	NA
Interest Expense	0.23	0.23	0.23	0.22	0.23	0.23	0.36	0.35	0.36	0.36	0.36	0.36	0.36	0.36	0.35	NA
Interest Expense Debt	0.20	0.20	0.20	0.20	0.30	0.20	0.40	0.40	0.30	0.40	0.40	0.40	0.20	0.40	0.40	NA
Interest Paid Net	0.14	0.14	0.14	0.14	0.14	0.15	0.34	0.34	0.34	0.34	0.34	0.34	0.34	0.34	NA	NA
Allocated Share Based Compensation Expense	5.05	5.18	6.57	5.39	5.14	5.96	5.63	4.49	5.85	2.54	1.35	1.18	1.00	0.99	0.95	NA
Income Tax Expense Benefit	0.05	0.02	0.00	0.02	-0.15	0.05	0.03	0.02	0.03	0.12	0.01	0.02	0.01	0.02	0.01	NA
Income Taxes Paid	0.03	NA	NA	NA	0.00	0.00	NA	NA	0.09	0.01	NA	NA	0.00	0.02	NA	NA
Other Comprehensive Income Loss Net Of Tax	0.01	0.00	-0.02	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Net Income Loss	-29.30	-21.57	-25.75	-21.43	-17.73	-20.40	-18.15	-15.44	-12.13	-8.60	-12.43	-8.43	-3.46	-4.45	-6.18	-4.21
Comprehensive Income Net Of Tax	-29.29	-21.57	-25.77	-21.43	-17.73	-20.40	-18.15	-15.44	-12.13	-8.60	-12.43	-8.43	-3.46	-4.45	-6.18	NA
Net Income Loss Available To Common Stockholders Basic	-29.30	-21.57	-25.75	-21.43	-17.73	-20.40	-18.15	-15.44	-12.13	-8.74	-13.23	-9.22	-4.27	-5.25	-6.98	NA
Net Income Loss Available To Common Stockholders Diluted	-29.30	-21.57	-25.75	-21.43	-17.73	-20.40	-18.15	-15.44	-12.13	-8.74	-13.23	-9.22	-4.27	-5.25	-6.98	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Assets 226.09 234.88 248.71 265.86 287.25 301.15 295.71 302.95 299.66 300.01 119.42 NA 131.01 NA NA NA

Liabilities 84.04 76.70 74.29 72.66 79.04 80.97 63.88 60.59 54.88 49.43 53.37 NA 47.23 NA NA NA

Liabilities And Stockholders Equity 226.09 234.88 248.71 265.86 287.25 301.15 295.71 302.95 299.66 300.01 119.42 NA 131.01 NA NA NA

Stockholders Equity 142.06 158.18 174.42 193.20 208.22 220.19 231.84 242.37 244.78 250.58 66.05 76.68 83.78 86.03 89.33 94.46

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Assets	226.09	234.88	248.71	265.86	287.25	301.15	295.71	302.95	299.66	300.01	119.42	NA	131.01	NA	NA	NA
Liabilities	84.04	76.70	74.29	72.66	79.04	80.97	63.88	60.59	54.88	49.43	53.37	NA	47.23	NA	NA	NA
Liabilities And Stockholders Equity	226.09	234.88	248.71	265.86	287.25	301.15	295.71	302.95	299.66	300.01	119.42	NA	131.01	NA	NA	NA
Stockholders Equity	142.06	158.18	174.42	193.20	208.22	220.19	231.84	242.37	244.78	250.58	66.05	76.68	83.78	86.03	89.33	94.46

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Assets Current 176.95 180.96 192.47 208.36 230.57 245.91 255.52 265.78 265.57 271.46 90.38 NA 105.35 NA NA NA

Cash 63.60 NA NA NA 152.96 NA NA NA NA NA NA NA NA NA NA NA

Cash And Cash Equivalents At Carrying Value 86.52 120.64 143.02 164.67 178.10 197.00 215.08 230.16 233.41 237.23 59.17 NA 81.03 NA NA NA

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 86.52 120.64 143.02 164.94 178.37 197.27 215.35 230.44 233.68 237.50 59.44 70.58 81.30 79.85 89.25 NA

Accounts Receivable Net Current 18.53 20.25 13.81 17.72 25.94 24.71 19.76 16.43 12.94 12.70 10.24 NA 9.33 NA NA NA

Inventory Net 18.86 15.71 15.66 15.66 14.55 13.21 12.57 10.94 11.05 12.84 11.91 NA 7.18 NA NA NA

Other Assets Current 2.88 3.48 3.23 3.54 3.94 3.83 3.99 3.69 2.83 2.60 2.63 NA 1.95 NA NA NA

Prepaid Expense And Other Assets Current 6.78 10.29 10.61 10.30 11.98 10.99 8.12 8.24 8.18 8.68 9.06 NA 7.80 NA NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Assets Current	176.95	180.96	192.47	208.36	230.57	245.91	255.52	265.78	265.57	271.46	90.38	NA	105.35	NA	NA	NA
Cash	63.60	NA	NA	NA	152.96	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cash And Cash Equivalents At Carrying Value	86.52	120.64	143.02	164.67	178.10	197.00	215.08	230.16	233.41	237.23	59.17	NA	81.03	NA	NA	NA
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents	86.52	120.64	143.02	164.94	178.37	197.27	215.35	230.44	233.68	237.50	59.44	70.58	81.30	79.85	89.25	NA
Accounts Receivable Net Current	18.53	20.25	13.81	17.72	25.94	24.71	19.76	16.43	12.94	12.70	10.24	NA	9.33	NA	NA	NA
Inventory Net	18.86	15.71	15.66	15.66	14.55	13.21	12.57	10.94	11.05	12.84	11.91	NA	7.18	NA	NA	NA
Other Assets Current	2.88	3.48	3.23	3.54	3.94	3.83	3.99	3.69	2.83	2.60	2.63	NA	1.95	NA	NA	NA
Prepaid Expense And Other Assets Current	6.78	10.29	10.61	10.30	11.98	10.99	8.12	8.24	8.18	8.68	9.06	NA	7.80	NA	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Property Plant And Equipment Gross 53.07 55.29 55.08 53.36 49.79 45.24 39.64 34.82 30.88 30.04 29.03 NA 28.64 NA NA NA

Accumulated Depreciation Depletion And Amortization Property Plant And Equipment 29.22 27.58 25.77 23.44 21.80 20.24 18.80 17.67 16.34 15.47 14.28 NA 12.17 NA NA NA

Property Plant And Equipment Net 23.85 27.70 29.32 29.91 27.99 25.00 20.84 17.15 14.54 14.56 14.76 NA 16.47 NA NA NA

Other Assets Noncurrent 1.97 2.10 2.40 1.99 2.36 3.19 3.36 3.53 2.56 0.98 1.02 NA 1.14 NA NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Property Plant And Equipment Gross	53.07	55.29	55.08	53.36	49.79	45.24	39.64	34.82	30.88	30.04	29.03	NA	28.64	NA	NA	NA
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment	29.22	27.58	25.77	23.44	21.80	20.24	18.80	17.67	16.34	15.47	14.28	NA	12.17	NA	NA	NA
Property Plant And Equipment Net	23.85	27.70	29.32	29.91	27.99	25.00	20.84	17.15	14.54	14.56	14.76	NA	16.47	NA	NA	NA
Other Assets Noncurrent	1.97	2.10	2.40	1.99	2.36	3.19	3.36	3.53	2.56	0.98	1.02	NA	1.14	NA	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Liabilities Current 45.49 34.38 29.14 27.71 32.75 34.31 27.49 39.61 28.97 23.79 22.57 NA 24.92 NA NA NA

Notes Payable Current 4.97 2.48 NA NA NA NA NA 16.59 11.59 6.59 1.60 NA 5.76 NA NA NA

Accounts Payable And Accrued Liabilities Current NA NA 11.95 9.92 12.43 10.21 10.50 8.15 8.40 8.31 8.10 NA 6.23 NA NA NA

Other Accrued Liabilities Current 1.62 1.42 0.66 0.64 1.14 1.06 0.53 0.48 0.46 0.42 1.00 NA 0.79 NA NA NA

Contract With Customer Liability Current 9.09 7.73 8.69 9.78 12.13 11.28 8.26 7.93 5.48 4.70 8.61 NA 9.69 NA NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Liabilities Current	45.49	34.38	29.14	27.71	32.75	34.31	27.49	39.61	28.97	23.79	22.57	NA	24.92	NA	NA	NA
Notes Payable Current	4.97	2.48	NA	NA	NA	NA	NA	16.59	11.59	6.59	1.60	NA	5.76	NA	NA	NA
Accounts Payable And Accrued Liabilities Current	NA	NA	11.95	9.92	12.43	10.21	10.50	8.15	8.40	8.31	8.10	NA	6.23	NA	NA	NA
Other Accrued Liabilities Current	1.62	1.42	0.66	0.64	1.14	1.06	0.53	0.48	0.46	0.42	1.00	NA	0.79	NA	NA	NA
Contract With Customer Liability Current	9.09	7.73	8.69	9.78	12.13	11.28	8.26	7.93	5.48	4.70	8.61	NA	9.69	NA	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Operating Lease Liability Noncurrent 22.73 23.56 24.14 23.57 24.34 25.09 14.84 15.36 15.90 11.19 11.44 NA 6.78 NA NA NA

		2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Operating Lease Liability Noncurrent		22.73	23.56	24.14	23.57	24.34	25.09	14.84	15.36	15.90	11.19	11.44	NA	6.78	NA	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Stockholders Equity 142.06 158.18 174.42 193.20 208.22 220.19 231.84 242.37 244.78 250.58 66.05 76.68 83.78 86.03 89.33 94.46

Common Stock Value 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 NA 0.00 NA NA NA

Additional Paid In Capital 503.71 490.54 485.21 478.23 471.82 466.06 457.31 449.68 436.66 430.34 12.43 NA 9.31 NA NA NA

Retained Earnings Accumulated Deficit -361.65 -332.35 -310.78 -285.03 -263.61 -245.88 -225.47 -207.32 -191.88 -179.76 -171.16 NA -150.30 NA NA NA

Accumulated Other Comprehensive Income Loss Net Of Tax -0.01 -0.02 -0.02 NA NA NA NA NA NA NA NA NA NA NA NA NA

Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 5.04 5.16 6.63 5.39 5.14 5.93 5.64 4.50 5.78 2.44 1.30 1.21 1.00 0.99 0.95 0.81

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Stockholders Equity	142.06	158.18	174.42	193.20	208.22	220.19	231.84	242.37	244.78	250.58	66.05	76.68	83.78	86.03	89.33	94.46
Common Stock Value	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	NA	0.00	NA	NA	NA
Additional Paid In Capital	503.71	490.54	485.21	478.23	471.82	466.06	457.31	449.68	436.66	430.34	12.43	NA	9.31	NA	NA	NA
Retained Earnings Accumulated Deficit	-361.65	-332.35	-310.78	-285.03	-263.61	-245.88	-225.47	-207.32	-191.88	-179.76	-171.16	NA	-150.30	NA	NA	NA
Accumulated Other Comprehensive Income Loss Net Of Tax	-0.01	-0.02	-0.02	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value	5.04	5.16	6.63	5.39	5.14	5.93	5.64	4.50	5.78	2.44	1.30	1.21	1.00	0.99	0.95	0.81

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Net Cash Provided By Used In Operating Activities -10.04 -16.91 -10.52 -10.07 -14.42 -14.62 -12.73 -11.36 -2.86 -12.01 -10.99 -9.99 3.33 -8.03 NA NA

Net Cash Provided By Used In Investing Activities -32.21 -5.64 -11.76 -4.38 -5.11 -6.33 -3.98 -0.40 -1.47 -0.51 -0.56 -0.76 -2.00 -1.95 NA NA

Net Cash Provided By Used In Financing Activities 8.12 0.18 0.35 1.02 0.62 2.87 1.63 8.52 0.50 190.58 0.41 0.02 0.12 0.58 NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Net Cash Provided By Used In Operating Activities	-10.04	-16.91	-10.52	-10.07	-14.42	-14.62	-12.73	-11.36	-2.86	-12.01	-10.99	-9.99	3.33	-8.03	NA	NA
Net Cash Provided By Used In Investing Activities	-32.21	-5.64	-11.76	-4.38	-5.11	-6.33	-3.98	-0.40	-1.47	-0.51	-0.56	-0.76	-2.00	-1.95	NA	NA
Net Cash Provided By Used In Financing Activities	8.12	0.18	0.35	1.02	0.62	2.87	1.63	8.52	0.50	190.58	0.41	0.02	0.12	0.58	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Net Cash Provided By Used In Operating Activities -10.04 -16.91 -10.52 -10.07 -14.42 -14.62 -12.73 -11.36 -2.86 -12.01 -10.99 -9.99 3.33 -8.03 NA NA

Net Income Loss -29.30 -21.57 -25.75 -21.43 -17.73 -20.40 -18.15 -15.44 -12.13 -8.60 -12.43 -8.43 -3.46 -4.45 -6.18 -4.21

Increase Decrease In Accounts Receivable -1.72 6.44 -3.91 -8.22 1.23 4.95 3.33 3.49 0.24 2.47 0.21 0.69 -11.51 14.29 NA NA

Increase Decrease In Inventories 0.56 -0.15 0.22 1.32 1.51 -0.59 2.97 2.74 -1.62 1.30 1.08 3.47 0.97 1.03 NA NA

Share Based Compensation 5.05 5.18 6.57 5.39 5.14 5.96 5.63 4.49 5.85 2.54 1.35 1.18 1.00 0.99 NA NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Net Cash Provided By Used In Operating Activities	-10.04	-16.91	-10.52	-10.07	-14.42	-14.62	-12.73	-11.36	-2.86	-12.01	-10.99	-9.99	3.33	-8.03	NA	NA
Net Income Loss	-29.30	-21.57	-25.75	-21.43	-17.73	-20.40	-18.15	-15.44	-12.13	-8.60	-12.43	-8.43	-3.46	-4.45	-6.18	-4.21
Increase Decrease In Accounts Receivable	-1.72	6.44	-3.91	-8.22	1.23	4.95	3.33	3.49	0.24	2.47	0.21	0.69	-11.51	14.29	NA	NA
Increase Decrease In Inventories	0.56	-0.15	0.22	1.32	1.51	-0.59	2.97	2.74	-1.62	1.30	1.08	3.47	0.97	1.03	NA	NA
Share Based Compensation	5.05	5.18	6.57	5.39	5.14	5.96	5.63	4.49	5.85	2.54	1.35	1.18	1.00	0.99	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Net Cash Provided By Used In Investing Activities -32.21 -5.64 -11.76 -4.38 -5.11 -6.33 -3.98 -0.40 -1.47 -0.51 -0.56 -0.76 -2.00 -1.95 NA NA

Payments To Acquire Property Plant And Equipment 0.34 0.97 2.38 4.38 5.11 6.33 3.98 0.40 1.47 0.51 0.56 0.76 2.00 2.30 NA NA

		2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Net Cash Provided By Used In Investing Activities		-32.21	-5.64	-11.76	-4.38	-5.11	-6.33	-3.98	-0.40	-1.47	-0.51	-0.56	-0.76	-2.00	-1.95	NA	NA
Payments To Acquire Property Plant And Equipment		0.34	0.97	2.38	4.38	5.11	6.33	3.98	0.40	1.47	0.51	0.56	0.76	2.00	2.30	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Net Cash Provided By Used In Financing Activities 8.12 0.18 0.35 1.02 0.62 2.87 1.63 8.52 0.50 190.58 0.41 0.02 0.12 0.58 NA NA

		2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Net Cash Provided By Used In Financing Activities		8.12	0.18	0.35	1.02	0.62	2.87	1.63	8.52	0.50	190.58	0.41	0.02	0.12	0.58	NA	NA

2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31

Revenues 17.84 21.40 19.15 20.21 23.19 24.32 19.25 18.63 21.75 18.21 10.57 13.78 16.62 15.67 11.76 12.64

Partnership Revenue Stream 1.22 2.61 NA NA 7.37 5.46 NA NA NA NA NA NA NA NA NA NA

Platform 10.20 11.76 NA NA 9.73 14.13 NA NA NA NA NA NA NA NA NA NA

Recurring 6.42 7.02 NA NA 6.08 4.73 NA NA NA NA NA NA NA NA NA NA

Partnership Revenue Stream, Service 1.22 2.61 NA NA 7.37 5.46 NA NA NA NA NA NA NA NA NA NA

Platform, Product 9.91 11.65 NA NA 9.36 13.70 NA NA NA NA NA NA NA NA NA NA

Platform, Service 0.30 0.11 NA NA 0.37 0.43 NA NA NA NA NA NA NA NA NA NA

Recurring, Product 3.83 4.30 NA NA 3.96 3.00 NA NA NA NA NA NA NA NA NA NA

Recurring, Service 2.58 2.72 NA NA 2.13 1.73 NA NA NA NA NA NA NA NA NA NA

Sales Channel Directly To Consumer NA NA 14.07 15.49 19.86 16.57 10.10 10.44 19.43 18.07 8.75 11.98 16.49 12.19 11.74 NA

Sales Channel Through Intermediary NA NA 5.08 4.72 3.33 7.76 9.15 8.19 2.32 0.14 1.82 1.80 0.13 3.48 0.03 NA

Agricultural Biology NA NA 1.85 1.49 1.54 0.64 NA NA NA NA NA NA NA NA NA NA

Antibody Therapeutics NA NA 12.98 14.22 17.09 18.44 13.67 15.11 17.04 12.96 9.96 11.82 10.62 14.98 11.45 NA

Cell Therapy NA NA 0.22 0.24 0.22 0.63 1.66 0.30 1.02 3.05 0.05 0.35 1.37 0.68 0.32 NA

Gene Therapy NA NA 2.03 1.77 1.77 2.05 2.06 1.23 NA NA NA NA NA NA NA NA

Synthetic Biology NA NA 2.07 2.47 2.56 2.56 1.86 1.98 3.68 2.19 0.57 1.61 4.63 0.00 0.00 NA

Product 13.74 15.95 9.47 9.77 13.32 16.70 13.02 13.53 17.69 14.10 9.11 10.68 12.94 13.20 7.79 NA

Service 4.10 5.45 9.68 10.43 9.87 7.62 6.23 5.09 4.05 4.11 1.46 3.10 3.68 2.47 3.97 NA

6.31 8.13 7.20 5.04 7.72 9.80 9.27 8.43 6.22 6.06 2.24 4.86 4.97 4.06 3.55 NA

6.11 3.95 2.06 1.46 1.61 3.39 1.11 2.83 4.19 5.10 2.66 0.44 2.79 2.29 5.00 NA

5.42 9.31 9.89 13.71 13.86 11.13 8.87 7.36 11.34 7.05 5.67 8.48 8.86 9.32 3.21 NA

Transferred At Point In Time NA NA NA 9.84 13.18 16.62 12.52 13.06 17.22 13.79 8.89 10.69 12.91 13.19 7.74 NA

Transferred Over Time NA NA NA 10.37 10.00 7.71 6.73 5.56 4.53 4.42 1.68 3.09 3.71 2.48 4.03 NA

Revenue From Contract With Customer Excluding Assessed Tax 17.84 21.40 19.15 20.21 23.19 24.32 19.25 18.63 21.75 18.21 10.57 13.78 16.62 15.67 11.76 12.64

Partnership Revenue Stream 1.22 2.61 NA NA 7.37 5.46 NA NA NA NA NA NA NA NA NA NA

Platform 10.20 11.76 NA NA 9.73 14.13 NA NA NA NA NA NA NA NA NA NA

Recurring 6.42 7.02 NA NA 6.08 4.73 NA NA NA NA NA NA NA NA NA NA

Partnership Revenue Stream, Service 1.22 2.61 NA NA 7.37 5.46 NA NA NA NA NA NA NA NA NA NA

Platform, Product 9.91 11.65 NA NA 9.36 13.70 NA NA NA NA NA NA NA NA NA NA

Platform, Service 0.30 0.11 NA NA 0.37 0.43 NA NA NA NA NA NA NA NA NA NA

Recurring, Product 3.83 4.30 NA NA 3.96 3.00 NA NA NA NA NA NA NA NA NA NA

Recurring, Service 2.58 2.72 NA NA 2.13 1.73 NA NA NA NA NA NA NA NA NA NA

Sales Channel Directly To Consumer NA NA 14.07 15.49 19.86 16.57 10.10 10.44 19.43 18.07 8.75 11.98 16.49 12.19 11.74 NA

Sales Channel Through Intermediary NA NA 5.08 4.72 3.33 7.76 9.15 8.19 2.32 0.14 1.82 1.80 0.13 3.48 0.03 NA

Agricultural Biology NA NA 1.85 1.49 1.54 0.64 NA NA NA NA NA NA NA NA NA NA

Antibody Therapeutics NA NA 12.98 14.22 17.09 18.44 13.67 15.11 17.04 12.96 9.96 11.82 10.62 14.98 11.45 NA

Cell Therapy NA NA 0.22 0.24 0.22 0.63 1.66 0.30 1.02 3.05 0.05 0.35 1.37 0.68 0.32 NA

Gene Therapy NA NA 2.03 1.77 1.77 2.05 2.06 1.23 NA NA NA NA NA NA NA NA

Synthetic Biology NA NA 2.07 2.47 2.56 2.56 1.86 1.98 3.68 2.19 0.57 1.61 4.63 0.00 0.00 NA

Product 13.74 15.95 9.47 9.77 13.32 16.70 13.02 13.53 17.69 14.10 9.11 10.68 12.94 13.20 7.79 NA

Service 4.10 5.45 9.68 10.43 9.87 7.62 6.23 5.09 4.05 4.11 1.46 3.10 3.68 2.47 3.97 NA

6.31 8.13 7.20 5.04 7.72 9.80 9.27 8.43 6.22 6.06 2.24 4.86 4.97 4.06 3.55 NA

6.11 3.95 2.06 1.46 1.61 3.39 1.11 2.83 4.19 5.10 2.66 0.44 2.79 2.29 5.00 NA

5.42 9.31 9.89 13.71 13.86 11.13 8.87 7.36 11.34 7.05 5.67 8.48 8.86 9.32 3.21 NA

Transferred At Point In Time NA NA NA 9.84 13.18 16.62 12.52 13.06 17.22 13.79 8.89 10.69 12.91 13.19 7.74 NA

Transferred Over Time NA NA NA 10.37 10.00 7.71 6.73 5.56 4.53 4.42 1.68 3.09 3.71 2.48 4.03 NA

	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31
Revenues	17.84	21.40	19.15	20.21	23.19	24.32	19.25	18.63	21.75	18.21	10.57	13.78	16.62	15.67	11.76	12.64
Partnership Revenue Stream	1.22	2.61	NA	NA	7.37	5.46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform	10.20	11.76	NA	NA	9.73	14.13	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring	6.42	7.02	NA	NA	6.08	4.73	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Partnership Revenue Stream, Service	1.22	2.61	NA	NA	7.37	5.46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform, Product	9.91	11.65	NA	NA	9.36	13.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform, Service	0.30	0.11	NA	NA	0.37	0.43	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring, Product	3.83	4.30	NA	NA	3.96	3.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring, Service	2.58	2.72	NA	NA	2.13	1.73	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sales Channel Directly To Consumer	NA	NA	14.07	15.49	19.86	16.57	10.10	10.44	19.43	18.07	8.75	11.98	16.49	12.19	11.74	NA
Sales Channel Through Intermediary	NA	NA	5.08	4.72	3.33	7.76	9.15	8.19	2.32	0.14	1.82	1.80	0.13	3.48	0.03	NA
Agricultural Biology	NA	NA	1.85	1.49	1.54	0.64	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Antibody Therapeutics	NA	NA	12.98	14.22	17.09	18.44	13.67	15.11	17.04	12.96	9.96	11.82	10.62	14.98	11.45	NA
Cell Therapy	NA	NA	0.22	0.24	0.22	0.63	1.66	0.30	1.02	3.05	0.05	0.35	1.37	0.68	0.32	NA
Gene Therapy	NA	NA	2.03	1.77	1.77	2.05	2.06	1.23	NA	NA	NA	NA	NA	NA	NA	NA
Synthetic Biology	NA	NA	2.07	2.47	2.56	2.56	1.86	1.98	3.68	2.19	0.57	1.61	4.63	0.00	0.00	NA
Product	13.74	15.95	9.47	9.77	13.32	16.70	13.02	13.53	17.69	14.10	9.11	10.68	12.94	13.20	7.79	NA
Service	4.10	5.45	9.68	10.43	9.87	7.62	6.23	5.09	4.05	4.11	1.46	3.10	3.68	2.47	3.97	NA
	6.31	8.13	7.20	5.04	7.72	9.80	9.27	8.43	6.22	6.06	2.24	4.86	4.97	4.06	3.55	NA
	6.11	3.95	2.06	1.46	1.61	3.39	1.11	2.83	4.19	5.10	2.66	0.44	2.79	2.29	5.00	NA
	5.42	9.31	9.89	13.71	13.86	11.13	8.87	7.36	11.34	7.05	5.67	8.48	8.86	9.32	3.21	NA
Transferred At Point In Time	NA	NA	NA	9.84	13.18	16.62	12.52	13.06	17.22	13.79	8.89	10.69	12.91	13.19	7.74	NA
Transferred Over Time	NA	NA	NA	10.37	10.00	7.71	6.73	5.56	4.53	4.42	1.68	3.09	3.71	2.48	4.03	NA
Revenue From Contract With Customer Excluding Assessed Tax	17.84	21.40	19.15	20.21	23.19	24.32	19.25	18.63	21.75	18.21	10.57	13.78	16.62	15.67	11.76	12.64
Partnership Revenue Stream	1.22	2.61	NA	NA	7.37	5.46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform	10.20	11.76	NA	NA	9.73	14.13	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring	6.42	7.02	NA	NA	6.08	4.73	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Partnership Revenue Stream, Service	1.22	2.61	NA	NA	7.37	5.46	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform, Product	9.91	11.65	NA	NA	9.36	13.70	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Platform, Service	0.30	0.11	NA	NA	0.37	0.43	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring, Product	3.83	4.30	NA	NA	3.96	3.00	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Recurring, Service	2.58	2.72	NA	NA	2.13	1.73	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Sales Channel Directly To Consumer	NA	NA	14.07	15.49	19.86	16.57	10.10	10.44	19.43	18.07	8.75	11.98	16.49	12.19	11.74	NA
Sales Channel Through Intermediary	NA	NA	5.08	4.72	3.33	7.76	9.15	8.19	2.32	0.14	1.82	1.80	0.13	3.48	0.03	NA
Agricultural Biology	NA	NA	1.85	1.49	1.54	0.64	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Antibody Therapeutics	NA	NA	12.98	14.22	17.09	18.44	13.67	15.11	17.04	12.96	9.96	11.82	10.62	14.98	11.45	NA
Cell Therapy	NA	NA	0.22	0.24	0.22	0.63	1.66	0.30	1.02	3.05	0.05	0.35	1.37	0.68	0.32	NA
Gene Therapy	NA	NA	2.03	1.77	1.77	2.05	2.06	1.23	NA	NA	NA	NA	NA	NA	NA	NA
Synthetic Biology	NA	NA	2.07	2.47	2.56	2.56	1.86	1.98	3.68	2.19	0.57	1.61	4.63	0.00	0.00	NA
Product	13.74	15.95	9.47	9.77	13.32	16.70	13.02	13.53	17.69	14.10	9.11	10.68	12.94	13.20	7.79	NA
Service	4.10	5.45	9.68	10.43	9.87	7.62	6.23	5.09	4.05	4.11	1.46	3.10	3.68	2.47	3.97	NA
	6.31	8.13	7.20	5.04	7.72	9.80	9.27	8.43	6.22	6.06	2.24	4.86	4.97	4.06	3.55	NA
	6.11	3.95	2.06	1.46	1.61	3.39	1.11	2.83	4.19	5.10	2.66	0.44	2.79	2.29	5.00	NA
	5.42	9.31	9.89	13.71	13.86	11.13	8.87	7.36	11.34	7.05	5.67	8.48	8.86	9.32	3.21	NA
Transferred At Point In Time	NA	NA	NA	9.84	13.18	16.62	12.52	13.06	17.22	13.79	8.89	10.69	12.91	13.19	7.74	NA
Transferred Over Time	NA	NA	NA	10.37	10.00	7.71	6.73	5.56	4.53	4.42	1.68	3.09	3.71	2.48	4.03	NA

Plots across concepts

IncomeStatement

Expenses

Balance Sheet

Assets

Current Assets

NonCurrent Assets

PropertyPlantAndEquipmentNet

Liabilities

Current Liabilities

Noncurrent Liabilities

Stockholders Equity

CashFlow

NetCashProvidedByUsedInOperatingActivities

NetCashProvidedByUsedInInvestingActivities

OperatingLeaseLiability

LesseeOperatingLeaseLiabilityPaymentsDue

InventoryNet

Line plots across dimensions of each concept

COGS Ratio
us-gaap:ProductOrService
(None,)

TTM Greenblatt ROC
_
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ProductOrService
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:ContractWithCustomerSalesChannel
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:TimingOfTransferOfGoodOrService
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:StatementGeographical
(None,)

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
bli:RevenueStream, us-gaap:ProductOrService
(None, 'us-gaap:Service')

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
bli:RevenueStream
(None,)

us-gaap:Revenues
us-gaap:ProductOrService
(None,)

us-gaap:Revenues
us-gaap:ContractWithCustomerSalesChannel
(None,)

us-gaap:Revenues
us-gaap:TimingOfTransferOfGoodOrService
(None,)

us-gaap:Revenues
us-gaap:StatementGeographical
(None,)

us-gaap:Revenues
bli:RevenueStream, us-gaap:ProductOrService
(None, 'us-gaap:Service')

us-gaap:Revenues
bli:RevenueStream
(None,)

us-gaap:CostOfGoodsAndServicesSold
us-gaap:ProductOrService
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:IncomeStatementLocation
(None,)

us-gaap:AllocatedShareBasedCompensationExpense
us-gaap:AwardType
(None,)

us-gaap:StockholdersEquity
us-gaap:StatementEquityComponents
(None,)

us-gaap:PropertyPlantAndEquipmentGross
us-gaap:PropertyPlantAndEquipmentByType
(None,)

us-gaap:LongTermDebtNoncurrent
us-gaap:DebtInstrument, us-gaap:LongtermDebtType
(None, 'us-gaap:NotesPayableToBanks')